Matt Phipps, Ph.D., is Group Head of Biotechnology Equity Research at William Blair & Co, LLC. He joined the firm in November 2014, after working as a postdoctoral research fellow at Texas Scottish Rite Hospital for Children. In the 2019 StarMine Analyst Awards from Refinitiv, Dr. Phipps was ranked the No. 1 earnings estimator in biotechnology and No. 3 across all industries. Dr. Phipps earned a Ph.D. in cellular and molecular physiology from the University of Alabama at Birmingham and a B.S. in physics in medicine from the University of Notre Dame.
New Drug Trials Spur Continued Interest in Anti-Obesity Space
October 20, 2024
Next-Generation Immune-Oncology Drugs Show Early Promise
March 30, 2023
Rising Interest Rates Pose Headwind for Biotechs Needing Cash
March 18, 2022
Broad Pullback in Biotech Provides Buying Opportunity for Specific Names
September 30, 2021
